2 results
Not approvedWill not start
Assess cognitive efficacy of gantenerumab, solanezumab in individuals who have mutations causing dominantly inherited Alzheimer's disease as measured by change in the DIAN-TU cognitive composite score between baseline and a minimum of 4 years.…
Approved WMOCompleted
Phase 1 - AMG 701 dose-exploration as monotherapyPrimary Objectives:• Evaluate the safety and tolerability of AMG 701 in subjects with relapsed/refractory multiple myeloma (RRMM) to determine the maximum tolerated dose (MTD) and/or recommended phase…